The baricitinib experience –a full review of Olumiant in RA
0 SAR
Checkout
Overview
Watch an animated video on the baricitinib experience, a review of Olumiant in RA conducted by Prof. Taylor with key outcomes from all RCTs and RWE.This Class for
- Physician
- Resident / Fellow
What I will learn?
- The animation video includes voice over and provides a more visual and engaging way of presenting the findings of the review. The animations make the data come to life and support the story told by the voice over artist.
Disclaimer
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)
For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
Please go to PDF Material for prescribing information
PP-BA-SA-1187
Related Classes
- EULAR 2025: How do risk factors impact progression to Psoriatic Arthritis?
- EULAR 2025 Symposium Highlights
- Rapid & Sustained efficacy in PsA and axSpA
- Effectiveness of Olumiant vs b-tsDMARDs over 2 years.
- Prof. Kleyer–BARE BONE –Olumiant and bone strength in RA.
- Exploring improvements in bone strength in RA with Olumiant.
- Real Patient Experience of Taltz in Psoriasis Arthritis
- Clinical Practice in Treating RA - From Expert to You